{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T19:31:10Z","timestamp":1717356670046},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,10,18]],"date-time":"2013-10-18T00:00:00Z","timestamp":1382054400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Patients diagnosed for a serous ovarian borderline tumor (s-BOT) typically present with an excellent clinical outcome. However there have been controversies concerning the prognostic impact of so-called implants, an extra ovarian spread occurring alongside the s-BOT in certain cases. It remains obscure whether these implants actually resemble metastasis owning the same genetic pattern as the ovarian primary or whether they develop independently.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The current study, in the aim of further clarifying the genetic origin of implants, assessed <jats:italic>BRAF\/KRAS<\/jats:italic> hot spot mutations and the p53\/p16<jats:sup>INK4a<\/jats:sup> immunophenotype of s-BOTs and corresponding implants (n\u2009=\u200949) of 15 patients by pyro-sequencing and immunostaining, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A significant proportion of both s-BOTs and implants showed <jats:italic>KRAS<\/jats:italic> or <jats:italic>BRAF<\/jats:italic> mutation and though p16<jats:sup>INK4a<\/jats:sup> was found to be abundantly expressed, p53 immunoreactivity was rather low. When genotypes of <jats:italic>BRAF\/KRAS<\/jats:italic> mutated s-BOTs and corresponding implants were compared no patient presented with a fully matching mutation profile of s-BOTs and all corresponding implants.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The current study reveals genetic heterogeneity of s-BOTs and implants, as none of the markers examined showed constant reciprocity. Hence, our findings may assist to explain the different clinical presentation of s-BOTs and implants and might encourage to applying more individualized follow up protocols.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-13-483","type":"journal-article","created":{"date-parts":[[2013,10,18]],"date-time":"2013-10-18T13:02:28Z","timestamp":1382101348000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants"],"prefix":"10.1186","volume":"13","author":[{"given":"Sabine","family":"Heublein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katinka","family":"Grasse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Hessel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Burges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Lenhard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jutta","family":"Engel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Kirchner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udo","family":"Jeschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doris","family":"Mayr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,18]]},"reference":[{"issue":"5","key":"4117_CR1","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/CCO.0b013e32833b0dc1","volume":"22","author":"WG McCluggage","year":"2010","unstructured":"McCluggage WG: The pathology of and controversial aspects of ovarian borderline tumours. Curr Opin Oncol. 2010, 22 (5): 462-472.","journal-title":"Curr Opin Oncol"},{"issue":"4","key":"4117_CR2","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","volume":"28","author":"A Malpica","year":"2004","unstructured":"Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG: Grading ovarian serous carcinoma using a two-tier system. Am j surg pathol. 2004, 28 (4): 496-504.","journal-title":"Am j surg pathol"},{"issue":"2","key":"4117_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ejogrb.2009.04.031","volume":"145","author":"MS Lenhard","year":"2009","unstructured":"Lenhard MS, Mitterer S, Kumper C, Stieber P, Mayr D, Ditsch N, Friese K, Burges A: Long-term follow-up after ovarian borderline tumor: relapse and survival in a large patient cohort. Eur J Obstet Gynecol Reprod Biol. 2009, 145 (2): 189-194.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"11","key":"4117_CR4","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1097\/01.pas.0000213294.81154.95","volume":"30","author":"EG Silva","year":"2006","unstructured":"Silva EG, Gershenson DM, Malpica A, Deavers M: The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. Am J Surg Pathol. 2006, 30 (11): 1367-1371.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"4117_CR5","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/j.1365-2559.2005.02186.x","volume":"47","author":"RJ Kurman","year":"2005","unstructured":"Kurman RJ, Seidman JD, Shih IM: Serous borderline tumours of the ovary. Histopathology. 2005, 47 (3): 310-315.","journal-title":"Histopathology"},{"issue":"10","key":"4117_CR6","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2157::AID-CNCR14>3.0.CO;2-D","volume":"83","author":"DM Gershenson","year":"1998","unstructured":"Gershenson DM, Silva EG, Tortolero-Luna G, Levenback C, Morris M, Tornos C: Serous borderline tumors of the ovary with noninvasive peritoneal implants. Cancer. 1998, 83 (10): 2157-2163.","journal-title":"Cancer"},{"issue":"5","key":"4117_CR7","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1053\/hp.2000.8048","volume":"31","author":"JD Seidman","year":"2000","unstructured":"Seidman JD, Kurman RJ: Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol. 2000, 31 (5): 539-557.","journal-title":"Hum Pathol"},{"issue":"4","key":"4117_CR8","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1093\/annonc\/mdg173","volume":"14","author":"P Morice","year":"2003","unstructured":"Morice P, Camatte S, Rey A, Atallah D, Lhomme C, Pautier P, Pomel C, Cote JF, Haie-Meder C, Duvillard P, et al: Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann Oncol Off J Eur Soc Med Oncol \/ ESMO. 2003, 14 (4): 592-598.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol \/ ESMO"},{"issue":"6","key":"4117_CR9","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/01.pas.0000164030.82810.db","volume":"29","author":"TA Longacre","year":"2005","unstructured":"Longacre TA, McKenney JK, Tazelaar HD, Kempson RL, Hendrickson MR: Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am J Surg Pathol. 2005, 29 (6): 707-723.","journal-title":"Am J Surg Pathol"},{"key":"4117_CR10","volume-title":"World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs","author":"FA Tavassoli","year":"2003","unstructured":"Tavassoli FA, Devilee P: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. 2003, Lyon: IARC Press"},{"issue":"3","key":"4117_CR11","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.ygyno.2006.05.029","volume":"103","author":"D Mayr","year":"2006","unstructured":"Mayr D, Hirschmann A, Lohrs U, Diebold J: KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol. 2006, 103 (3): 883-887.","journal-title":"Gynecol Oncol"},{"issue":"8","key":"4117_CR12","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","volume":"1773","author":"JA McCubrey","year":"2007","unstructured":"McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, et al: Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007, 1773 (8): 1263-1284.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"4117_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5301\/JBM.2011.8737","volume":"27","author":"J Radojicic","year":"2012","unstructured":"Radojicic J, Zaravinos A, Spandidos DA: HPV, KRAS mutations, alcohol consumption and tobacco smoking effects on esophageal squamous-cell carcinoma carcinogenesis. Int J Biol Markers. 2012, 27 (1): 1-12.","journal-title":"Int J Biol Markers"},{"issue":"5","key":"4117_CR14","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.ccr.2010.10.020","volume":"18","author":"KE Lee","year":"2010","unstructured":"Lee KE, Bar-Sagi D: Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells. Cancer Cell. 2010, 18 (5): 448-458.","journal-title":"Cancer Cell"},{"issue":"7","key":"4117_CR15","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1002\/ijc.24467","volume":"125","author":"ML Slattery","year":"2009","unstructured":"Slattery ML, Wolff RK, Herrick J, Caan BJ, Samowitz W: Tumor markers and rectal cancer: support for an inflammation-related pathway. Int J Cancer J Int Du Cancer. 2009, 125 (7): 1698-1704.","journal-title":"Int J Cancer J Int Du Cancer"},{"issue":"11","key":"4117_CR16","first-page":"2914","volume":"54","author":"SP Dowell","year":"1994","unstructured":"Dowell SP, Wilson PO, Derias NW, Lane DP, Hall PA: Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cancer Res. 1994, 54 (11): 2914-2918.","journal-title":"Cancer Res"},{"issue":"15","key":"4117_CR17","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/sj.onc.1210280","volume":"26","author":"T Soussi","year":"2007","unstructured":"Soussi T: p53 alterations in human cancer: more questions than answers. Oncogene. 2007, 26 (15): 2145-2156.","journal-title":"Oncogene"},{"issue":"3","key":"4117_CR18","first-page":"189","volume":"38","author":"L Zong","year":"2012","unstructured":"Zong L, Chen P, Xu Y: Correlation between P53 expression and malignant risk of gastrointestinal stromal tumors: evidence from 9 studies. Eur J Surg Oncol J Eur Soc Surg Oncol British Assoc Surg Oncol. 2012, 38 (3): 189-195.","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol British Assoc Surg Oncol"},{"issue":"10","key":"4117_CR19","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.neurol.2011.07.006","volume":"167","author":"D Figarella Branger","year":"2011","unstructured":"Figarella Branger D, Maues De Paula A, Colin C, Bouvier C: Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers. Revue Neurol. 2011, 167 (10): 683-690.","journal-title":"Revue Neurol"},{"issue":"3","key":"4117_CR20","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s12253-010-9345-8","volume":"17","author":"I Vereczkey","year":"2011","unstructured":"Vereczkey I, Serester O, Dobos J, Gallai M, Szakacs O, Szentirmay Z, Toth E: Molecular characterization of 103 ovarian serous and mucinous tumors. Pathol Oncol Res. 2011, 17 (3): 551-559.","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"4117_CR21","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ygyno.2008.09.008","volume":"112","author":"I Ziolkowska-Seta","year":"2009","unstructured":"Ziolkowska-Seta I, Madry R, Kraszewska E, Szymanska T, Timorek A, Rembiszewska A, Kupryjanczyk J: TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens. Gynecol Oncol. 2009, 112 (1): 179-184.","journal-title":"Gynecol Oncol"},{"issue":"11","key":"4117_CR22","first-page":"2979","volume":"51","author":"JR Marks","year":"1991","unstructured":"Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast RC, Berchuck A: Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer res. 1991, 51 (11): 2979-2984.","journal-title":"Cancer res"},{"issue":"4","key":"4117_CR23","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1080\/02841860802047411","volume":"47","author":"J Alsner","year":"2008","unstructured":"Alsner J, Jensen V, Kyndi M, Offersen BV, Vu P, Borresen-Dale AL, Overgaard J: A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol. 2008, 47 (4): 600-607.","journal-title":"Acta Oncol"},{"issue":"8","key":"4117_CR24","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/01.pas.0000166367.68459.7d","volume":"29","author":"CJ O'Neill","year":"2005","unstructured":"O'Neill CJ, Deavers MT, Malpica A, Foster H, McCluggage WG: An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2\/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol. 2005, 29 (8): 1034-1041.","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"4117_CR25","first-page":"147","volume":"26","author":"H Brustmann","year":"2007","unstructured":"Brustmann H: Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome. Int J Gynecol Pathol Off J Int Soc Gynecol Pathol. 2007, 26 (2): 147-153.","journal-title":"Int J Gynecol Pathol Off J Int Soc Gynecol Pathol"},{"issue":"4","key":"4117_CR26","first-page":"967","volume":"53","author":"LN Giurgea","year":"2012","unstructured":"Giurgea LN, Ungureanu C, Mihailovici MS: The immunohistochemical expression of p53 and Ki67 in ovarian epithelial borderline tumors. Correlation with clinicopathological factors. Rom J Morphol Embryol Revue Roumaine De Morphol Et Embryol. 2012, 53 (4): 967-973.","journal-title":"Rom J Morphol Embryol Revue Roumaine De Morphol Et Embryol"},{"issue":"3","key":"4117_CR27","first-page":"138","volume":"8","author":"W Remmele","year":"1987","unstructured":"Remmele W, Stegner HE: [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe. 1987, 8 (3): 138-140.","journal-title":"Pathologe"},{"issue":"4","key":"4117_CR28","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1002\/ijc.26467","volume":"131","author":"DP Modest","year":"2012","unstructured":"Modest DP, Jung A, Moosmann N, Laubender RP, Giessen C, Schulz C, Haas M, Neumann J, Boeck S, Kirchner T, et al: The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: An analysis of the AIO KRK-0104-trial. Int J Cancer J Int Du Cancer. 2012, 131 (4): 980-986.","journal-title":"Int J Cancer J Int Du Cancer"},{"issue":"12","key":"4117_CR29","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.prp.2009.07.010","volume":"205","author":"J Neumann","year":"2009","unstructured":"Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A: Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract. 2009, 205 (12): 858-862.","journal-title":"Pathol Res Pract"},{"key":"4117_CR30","volume-title":"Genetic Analysis of Ovarian Carcinoma Histogenesis","author":"B Pothuri","year":"2001","unstructured":"Pothuri B, Leitao M, Barakat R, et al: Abstract in Society of Gynecologic Oncologists, 32nd Annual Meeting. Genetic Analysis of Ovarian Carcinoma Histogenesis. 2001"},{"issue":"2","key":"4117_CR31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/01.pas.0000213335.40358.47","volume":"31","author":"DW Kindelberger","year":"2007","unstructured":"Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C, et al: Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol. 2007, 31 (2): 161-169.","journal-title":"Am J Surg Pathol"},{"issue":"19","key":"4117_CR32","doi-asserted-by":"publisher","first-page":"6915","DOI":"10.1158\/0008-5472.CAN-04-2067","volume":"64","author":"CL Ho","year":"2004","unstructured":"Ho CL, Kurman RJ, Dehari R, Wang TL, Shih Ie M: Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res. 2004, 64 (19): 6915-6918.","journal-title":"Cancer Res"},{"issue":"6","key":"4117_CR33","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/labinvest.3700103","volume":"84","author":"EJ Cheng","year":"2004","unstructured":"Cheng EJ, Kurman RJ, Wang M, Oldt R, Wang BG, Berman DM, Shih Ie M: Molecular genetic analysis of ovarian serous cystadenomas. Lab Invest. 2004, 84 (6): 778-784.","journal-title":"Lab Invest"},{"issue":"3","key":"4117_CR34","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/path.3967","volume":"226","author":"S Jones","year":"2012","unstructured":"Jones S, Wang TL, Kurman RJ, Nakayama K, Velculescu VE, Vogelstein B, Kinzler KW, Papadopoulos N, Shih Ie M: Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol. 2012, 226 (3): 413-420.","journal-title":"J Pathol"},{"issue":"5","key":"4117_CR35","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/S0002-9440(10)63708-X","volume":"164","author":"M Shih Ie","year":"2004","unstructured":"Shih Ie M, Kurman RJ: Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004, 164 (5): 1511-1518.","journal-title":"Am J Pathol"},{"issue":"4","key":"4117_CR36","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ijc.11107","volume":"105","author":"NA Thomas","year":"2003","unstructured":"Thomas NA, Neville PJ, Baxter SW, Campbell IG: Genetic analysis of benign ovarian tumors. Int J Cancer J Int Du Cancer. 2003, 105 (4): 499-505.","journal-title":"Int J Cancer J Int Du Cancer"},{"issue":"4","key":"4117_CR37","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.2353\/ajpath.2010.100212","volume":"177","author":"KK Wong","year":"2010","unstructured":"Wong KK, Tsang YT, Deavers MT, Mok SC, Zu Z, Sun C, Malpica A, Wolf JK, Lu KH, Gershenson DM: BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol. 2010, 177 (4): 1611-1617.","journal-title":"Am J Pathol"},{"issue":"9","key":"4117_CR38","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1097\/CAD.0b013e3283493160","volume":"22","author":"DP Modest","year":"2011","unstructured":"Modest DP, Stintzing S, Laubender RP, Neumann J, Jung A, Giessen C, Haas M, Aubele P, Schulz C, Boeck S, et al: Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status. Anti-cancer Drugs. 2011, 22 (9): 913-918.","journal-title":"Anti-cancer Drugs"},{"issue":"7","key":"4117_CR39","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/modpathol.2011.43","volume":"24","author":"L Kriegl","year":"2011","unstructured":"Kriegl L, Neumann J, Vieth M, Greten FR, Reu S, Jung A, Kirchner T: Up and downregulation of p16(Ink4a) expression in BRAF-mutated polyps\/adenomas indicates a senescence barrier in the serrated route to colon cancer. Mod Pathol Off J United States Can Acad Pathol Inc. 2011, 24 (7): 1015-1022.","journal-title":"Mod Pathol Off J United States Can Acad Pathol Inc"},{"issue":"12","key":"4117_CR40","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1097\/PAS.0b013e3181b6da19","volume":"33","author":"S Yachida","year":"2009","unstructured":"Yachida S, Mudali S, Martin SA, Montgomery EA, Iacobuzio-Donahue CA: Beta-catenin nuclear labeling is a common feature of sessile serrated adenomas and correlates with early neoplastic progression after BRAF activation. Am J Surg Pathol. 2009, 33 (12): 1823-1832.","journal-title":"Am J Surg Pathol"},{"key":"4117_CR41","volume-title":"Pathologie-biologie","author":"N Marchoudi","year":"2013","unstructured":"Marchoudi N, Amrani Hassani Joutei H, Jouali F, Fekkak J, Rhaissi H: Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer. Pathologie-biologie. 2013"},{"issue":"12","key":"4117_CR42","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1038\/sj.bjc.6604783","volume":"99","author":"N Nakayama","year":"2008","unstructured":"Nakayama N, Nakayama K, Yeasmin S, Ishibashi M, Katagiri A, Iida K, Fukumoto M, Miyazaki K: KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. British J Cancer. 2008, 99 (12): 2020-2028.","journal-title":"British J Cancer"},{"issue":"3","key":"4117_CR43","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/path.1521","volume":"202","author":"NL Sieben","year":"2004","unstructured":"Sieben NL, Macropoulos P, Roemen GM, Kolkman-Uljee SM, Jan Fleuren G, Houmadi R, Diss T, Warren B, Al Adnani M, De Goeij AP, et al: In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol. 2004, 202 (3): 336-340.","journal-title":"J Pathol"},{"issue":"4","key":"4117_CR44","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/pgp.0b013e3180336287","volume":"26","author":"RE Emerson","year":"2007","unstructured":"Emerson RE, Wang M, Liu F, Lawrence WD, Abdul-Karim FW, Cheng L: Molecular genetic evidence of an independent origin of serous low malignant potential implants and lymph node inclusions. Int J Gynecol Pathol Off J Int Soc Gynecol Pathol. 2007, 26 (4): 387-394.","journal-title":"Int J Gynecol Pathol Off J Int Soc Gynecol Pathol"},{"issue":"15","key":"4117_CR45","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/jnci\/93.15.1147","volume":"93","author":"J Gu","year":"2001","unstructured":"Gu J, Roth LM, Younger C, Michael H, Abdul-Karim FW, Zhang S, Ulbright TM, Eble JN, Cheng L: Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential. J Natl Cancer Inst. 2001, 93 (15): 1147-1152.","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"4117_CR46","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1093\/jnci\/84.23.1793","volume":"84","author":"IJ Jacobs","year":"1992","unstructured":"Jacobs IJ, Kohler MF, Wiseman RW, Marks JR, Whitaker R, Kerns BA, Humphrey P, Berchuck A, Ponder BA, Bast RC: Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst. 1992, 84 (23): 1793-1798.","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"4117_CR47","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1002\/ijc.24148","volume":"124","author":"L Khalique","year":"2009","unstructured":"Khalique L, Ayhan A, Whittaker JC, Singh N, Jacobs IJ, Gayther SA, Ramus SJ: The clonal evolution of metastases from primary serous epithelial ovarian cancers. Int J Cancer J Int Du Cancer. 2009, 124 (7): 1579-1586.","journal-title":"Int J Cancer J Int Du Cancer"},{"issue":"3","key":"4117_CR48","first-page":"166","volume":"9","author":"J Kupryjanczyk","year":"1996","unstructured":"Kupryjanczyk J, Thor AD, Beauchamp R, Poremba C, Scully RE, Yandell DW: Ovarian, peritoneal, and endometrial serous carcinoma: clonal origin of multifocal disease. Mod Pathol Off J United States Can Acad Pathol Inc. 1996, 9 (3): 166-173.","journal-title":"Mod Pathol Off J United States Can Acad Pathol Inc"},{"issue":"11","key":"4117_CR49","first-page":"2328","volume":"58","author":"KH Lu","year":"1998","unstructured":"Lu KH, Bell DA, Welch WR, Berkowitz RS, Mok SC: Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Cancer Res. 1998, 58 (11): 2328-2330.","journal-title":"Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-483.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-13-483\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-483","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-483.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T02:02:15Z","timestamp":1630548135000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-13-483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,18]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["4117"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-13-483","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,18]]},"assertion":[{"value":"10 July 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"483"}}